关键信息
-
基因名
Adamts13
- 应用
-
别名
Adamts13；C9orf8；A disintegrin and metalloProteinase with thrombospondin motifs 13
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q76LX8
-
表达区间
1328-1427aa
-
氨基酸序列
FINVAPHARIAIHALATNMGAGTEGANASYILIRDTHSLRTTAFHGQQVL YWESESSQAEMEFSEGFLKAQASLRGQYWTLQSWVPEMQDPQSWKGKEGT
-
分子量
37 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
ADAMTS13 is a metalloproteinase that plays a crucial role in the regulation of von Willebrand factor (VWF) in the bloodstream. It is primarily responsible for cleaving large VWF multimers into smaller, functionally active forms, thereby preventing excessive platelet aggregation and the formation of thrombi. Deficiencies or dysfunctions in ADAMTS13 are linked to disordered blood coagulation states, particularly thrombotic thrombocytopenic purpura (TTP), a life-threatening condition characterized by microangiopathic hemolytic anemia and thrombocytopenia. Research into recombinant ADAMTS13 has emerged as a potential therapeutic strategy for TTP and similar coagulation disorders. Recombinant forms of ADAMTS13 aim to restore its function in patients with congenital or acquired deficiencies. Additionally, understanding the structure-function relationship and the molecular mechanisms of ADAMTS13 can provide insights into its role in hemostasis and thrombosis. Studies have focused on optimizing the production and stability of recombinant ADAMTS13 to enhance its clinical efficacy. The therapeutic potential of this protein underscores the importance of ongoing research to develop effective treatments for conditions associated with VWF dysregulation, ultimately improving patient outcomes in coagulation disorders.
